Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × ESCC × camrelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 36 Carcinoma, Non-Small-Cell Lung 19 Stomach Neoplasms 17 Triple Negative Breast Neoplasms 16 Nasopharyngeal Carcinoma 16 Esophageal Squamous Cell Carcinoma 14 Esophageal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 13 Breast Neoplasms 12 Colorectal Neoplasms 10 Uterine Cervical Neoplasms 8 Pancreatic Neoplasms 7 Recurrence 6 Neoplasm Metastasis 6 Melanoma 6 Liver Neoplasms 6 Lung Neoplasms 5 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Neoplasms 4 Locally Advanced Gastric Cancer 4 Hodgkin Disease 4 Advanced Gastric Cancer 4 Sarcoma 3 Rectal Neoplasms 3 Osteosarcoma 3 Nasopharyngeal Neoplasms 3 Glioblastoma 3 Gestational Trophoblastic Disease 3 Urinary Bladder Neoplasms 2

Interventions

trifluridine tipiracil drug combination 1 camrelizumab 1 anlotinib 1 Radiotherapy 1 Induction Chemotherapy 1 Immunotherapy 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05050760 2023-01-31

DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer

Xijing Hospital

Phase NA Unknown

ESCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡